Horizon Therapeutics Names Timothy P. Walbert as President and CEO

Jul 24, 2008, 01:00 ET from Horizon Therapeutics, Inc.

    PALO ALTO, Calif., July 24 /PRNewswire/ -- Horizon Therapeutics, Inc.,
 a privately held biopharmaceutical company, today announced that Timothy P.
 Walbert has been named president, chief executive officer and member of the
 board of directors of Horizon Therapeutics.
 
     "Tim has a long, proven track record of successfully commercializing
 multi-billion dollar drugs in the pain and arthritis areas," said George
 Tidmarsh, M.D., Ph.D., founder, scientific consultant and board member of
 Horizon. "Tim has the perfect background to lead our company as we move
 toward the unblinding of the Phase 3 clinical data for our lead product
 candidate HZT-501, a proprietary formulation of ibuprofen combined with
 famotidine in a single pill. We are thrilled to have someone of his caliber
 joining Horizon."
 
     Mr. Walbert has nearly two decades of executive, general management,
 marketing and sales experience in the pharmaceutical and biotech
 industries. Mr. Walbert is currently president and chief executive officer
 of IDM Pharma (Nasdaq:   IDMI), a biopharmaceutical company focused on the
 development of innovative products that activate the immune system to treat
 cancer. Prior to IDM Pharma, Mr. Walbert served as executive vice
 president, commercial operations at NeoPharm, Inc.
 
     Mr. Walbert previously was at Abbott where he served as divisional vice
 president and general manager of Abbott Immunology and divisional vice
 president of global cardiovascular marketing. Under his leadership, he was
 responsible for the creation of Abbott Immunology through the approval,
 launch and commercialization of HUMIRA(R) for the treatment of rheumatoid
 arthritis in the United States, Europe and other countries. HUMIRA became
 the most successful launch in Abbott's history, achieving sales of more
 than $1.4 billion by 2005 and is expected to exceed $3 billion in 2008.
 
     Mr. Walbert also served as director, Celebrex(R) North America and
 arthritis team leader, Asia Pacific, Latin America and Canada at
 Searle/Pharmacia. He coordinated Celebrex activities in Canada, Australia,
 and Latin America where aggregate sales grew to nearly $400 million in
 2000, making it one of the most successful pharmaceutical products launched
 in many of those countries. Mr. Walbert also held a number of other key
 marketing and sales positions with Searle/Pharmacia, which included the
 U.S. launch of Arthrotec(R), a combination arthritis/pain product which
 generated more than $200 million in first year sales in 1998 and Daypro(R),
 an arthritis/pain product which generated more than $300 million in peak
 U.S. sales.
 
     "I am excited by the opportunity to lead Horizon and help bring a new
 therapeutic option to market that may offer patients effective pain relief
 with GI-protection," said Mr. Walbert. "Approximately 25 percent of regular
 NSAID users may develop stomach ulcers and there continues to be a
 significant unmet treatment need for effective pain relief while lowering a
 patient's risk of developing these ulcers. Horizon is well positioned to
 address this need and become a market leader."
 
     About Horizon Therapeutics
 
     Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company
 focused on the development and commercialization of therapies for the
 treatment of mild-to-moderate pain and arthritis. Horizon's clinical
 portfolio includes innovative combination therapies in early- and
 late-stage development that are designed to improve safety, efficacy, and
 patient compliance. For more information about the company and its
 products, please visit http://www.horizontherapeutics.com.
 
 
 

SOURCE Horizon Therapeutics, Inc.
    PALO ALTO, Calif., July 24 /PRNewswire/ -- Horizon Therapeutics, Inc.,
 a privately held biopharmaceutical company, today announced that Timothy P.
 Walbert has been named president, chief executive officer and member of the
 board of directors of Horizon Therapeutics.
 
     "Tim has a long, proven track record of successfully commercializing
 multi-billion dollar drugs in the pain and arthritis areas," said George
 Tidmarsh, M.D., Ph.D., founder, scientific consultant and board member of
 Horizon. "Tim has the perfect background to lead our company as we move
 toward the unblinding of the Phase 3 clinical data for our lead product
 candidate HZT-501, a proprietary formulation of ibuprofen combined with
 famotidine in a single pill. We are thrilled to have someone of his caliber
 joining Horizon."
 
     Mr. Walbert has nearly two decades of executive, general management,
 marketing and sales experience in the pharmaceutical and biotech
 industries. Mr. Walbert is currently president and chief executive officer
 of IDM Pharma (Nasdaq:   IDMI), a biopharmaceutical company focused on the
 development of innovative products that activate the immune system to treat
 cancer. Prior to IDM Pharma, Mr. Walbert served as executive vice
 president, commercial operations at NeoPharm, Inc.
 
     Mr. Walbert previously was at Abbott where he served as divisional vice
 president and general manager of Abbott Immunology and divisional vice
 president of global cardiovascular marketing. Under his leadership, he was
 responsible for the creation of Abbott Immunology through the approval,
 launch and commercialization of HUMIRA(R) for the treatment of rheumatoid
 arthritis in the United States, Europe and other countries. HUMIRA became
 the most successful launch in Abbott's history, achieving sales of more
 than $1.4 billion by 2005 and is expected to exceed $3 billion in 2008.
 
     Mr. Walbert also served as director, Celebrex(R) North America and
 arthritis team leader, Asia Pacific, Latin America and Canada at
 Searle/Pharmacia. He coordinated Celebrex activities in Canada, Australia,
 and Latin America where aggregate sales grew to nearly $400 million in
 2000, making it one of the most successful pharmaceutical products launched
 in many of those countries. Mr. Walbert also held a number of other key
 marketing and sales positions with Searle/Pharmacia, which included the
 U.S. launch of Arthrotec(R), a combination arthritis/pain product which
 generated more than $200 million in first year sales in 1998 and Daypro(R),
 an arthritis/pain product which generated more than $300 million in peak
 U.S. sales.
 
     "I am excited by the opportunity to lead Horizon and help bring a new
 therapeutic option to market that may offer patients effective pain relief
 with GI-protection," said Mr. Walbert. "Approximately 25 percent of regular
 NSAID users may develop stomach ulcers and there continues to be a
 significant unmet treatment need for effective pain relief while lowering a
 patient's risk of developing these ulcers. Horizon is well positioned to
 address this need and become a market leader."
 
     About Horizon Therapeutics
 
     Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company
 focused on the development and commercialization of therapies for the
 treatment of mild-to-moderate pain and arthritis. Horizon's clinical
 portfolio includes innovative combination therapies in early- and
 late-stage development that are designed to improve safety, efficacy, and
 patient compliance. For more information about the company and its
 products, please visit http://www.horizontherapeutics.com.
 
 
 SOURCE Horizon Therapeutics, Inc.